PR

MEZOO, connecting health through technology
Sharing MEZOO’s technology and vision.
자료실
2026.03.03
Notice of Issuance of New Shares

Notice of Issuance of New Shares

 

The Company hereby gives notice pursuant to Article 418 Paragraph 4 of the Commercial Act that the Board of Directors resolved on January 16, 2026 to issue new shares in connection with the listing on the KOSDAQ Market as follows. 


1. Type and number of new shares Registered common shares: 1,385,350 – 1,398,800 shares (par value KRW 500)

Classification

Type of Securities

Offering
Method

Par Value

Number
of Shares

New Share Offering

Registered
Common Shares

Public
Offering

KRW 500

1,345,000
shares

Underwriter Mandatory Subscription

Registered
Common Shares

Private
Placement

KRW 500

40,350 shares

Underwriter Mandatory Acquisition

Registered
Common Shares

Private
Placement

KRW 500

0 – 13,450
shares


2. 
Offering Price

In accordance with Article 5 of the “Regulations on Underwriting Business of Securities,” the final offering price shall be determined by the Chief Executive Officer in consultation with Shinhan Securities Co., Ltd., the lead underwriter for the Company’s KOSDAQ listing, taking into account the results of the demand forecast and market conditions.

3. Allocation of the Offered Shares

1) The offered shares shall be allocated in accordance with Article 9 of the Regulations on Underwriting Business of Securities.

2) The allocation method and detailed terms may be changed based on the results of the demand forecast and subscription, and the detailed plan shall be delegated to the Chief Executive Officer.


4. 
Method of Underwriting

All of the offered shares shall be fully underwritten (100%) by the lead underwriter, Shinhan Securities Co., Ltd., and other matters shall be determined by the Chief Executive Officer.

5. Payment Date March 19, 2026 (scheduled)

The payment date may be determined by the Chief Executive Officer depending on the effective date of the securities registration statement filed with the Financial Supervisory Service and the offering schedule.


6. 
Paying Bank : Shinhan Bank, Wonju Financial Center

(If changes are required, the authority to determine such changes shall be delegated to the Chief Executive Officer.)


7. 
Preemptive Rights : In accordance with Article 10 Paragraph 2 of the Articles of Incorporation of the Company, the preemptive rights of existing shareholders shall be excluded.


8. 
Contribution in Kind : Not applicable.


9. 
Other Matters

The above matters may be changed depending on the results of demand forecasting and consultation with shareholders and the lead underwriter. Detailed matters are delegated to the Chief Executive Officer. 


March 3, 2026

 

MEZOO Co., Ltd.

808, 200 Gieopdosi-ro, Jijeong-myeon

Wonju-si, Gangwon Special Self-Governing Province, Republic of Korea

(Medical Device Industry Support Center)

Chief Executive Officer

Jung Hwan Park

적용 법률 및 규정
의료기기

하이카디® 시스템은 인허가에 따라 신생아, 소아, 청소년, 18세 이상 환자의 ECG 데이터를 측정하여 부정맥을 진단하는 의료기기로서 의료전문가가 사용하도록 설계되었습니다. 한국 KFDA로부터 의료기기 2등급 인증을 받았습니다. 유럽의료기기 지침(2007/47/EC에 따라 개정된 MDD 93/42/EEC)에 따라 준수된 Class IIb (CE2265). 의료기기 제품으로 CE 승인되었습니다. 미국 FDA는 Class II 510K로 승인 완료 예정입니다.

경고

본 자료는 의료 전문가에게만 배포되며 관련 사진과 함께 제공되는 자료와 관련하여 그 어떤 법적인 책임을 갖지 않습니다. 사용 전 사용 지침서를 주의 깊게 읽으십시오.